Erythropoietin Drugs Market Report, published by Allied Market Research, forecasts that the global market is expected to garner $11.9 billion by 2020, registering a CAGR of 9.7% during the period 2014 - 2020.
- Advertising -
Commercialization of a potent version of Erythropoietin alfa namely Darbepotin alfa reveals lucrative opportunities within the EPO drugs market. Darbepotin alfa that is potent (as compared to other EPO drugs) is effective at smaller dosage, thus results lesser side effects than its peers.
Hence, Darbepotin alfa is increasingly preferred by the customers (doctors). Also, patent protection for Darbepotin alfa will expire by 2016, hence, manufacturers of generic EPO drugs/biosimilars can target e…into this market.
Get PDF Brochure For Details: www.alliedmarketresearch.com/request-sample/59
In terms of applications, sale of EPO drugs targeted for treating kidney disorders (ESRD and dialysis) proves lucrative; as usage of EPO drugs is mandatory and irreplaceable (by indirect substitutes) for treating kidney disorders.
- Advertising -
In case of oncological disorders, usage of radiation therapy is increasingly replacing chemotherapy; declining usage of chemotherapy consequently reduces the demand for EPO drugs (in treatment of oncological disorders).
The global EPO drugs market is thus driven by increasing number of patients suffering from anemic condition induced due to cancer, HIV and ESRD treatment; favorable reimbursements and increasing commercialization of EPO biosimilars. Amongst all synthetic erythropoietin products, Epoetin alfa and its advance version, Darbepoetin alfa, are the most popular drugs.
Epoetin alfa and Darbepoetin alfa collectively accounted for ~80% of total EPO drugs market revenue. Amgen Inc. was first company to innovate Epoetin alfa and Darbepoetin alfa that are branded/patented as Epogen and Aranesp respectively.
However, expiration of Amgen’s patent for Epogen has aided manufacturers of biosimilars to enter the EPO drugs market. Availability of numerous biosimilars has rendered low-cost option to the patients, therefore increased adoption rates for EPO drugs particularly in the developing regions.
Enquiry About Report: www.alliedmarketresearch.com/purchase-enquiry/59
Based on the applications, the global EPO drugs market is segmented into anemia associated with End Stage Renal Diseases (ESRD), cancer chemotherapy and, antiretroviral treatment (ART). Current research is focused toward expanding the applications of EPO drugs in other disease conditions such as neural diseases and wound healing.
GlobalErythropoietin drugs market is segmented based on geography into North America, Europe, Asia Pacific and LAMEA. Europe is the leading geographical market owing to favorable reimbursement policies and less stringent and speedy regulatory approvals for EPO drugs.
ERYTHROPOIETIN DRUGS MARKET KEY SEGMENTATION
The global EPO drugs market is segmented based on products, applications and geography.
BY PRODUCT TYPES
- Anemia (Cancer and HIV treatment)
- Kidney Disorders (ESRD and Dialysis)
- Others (Neural Disease and Wound healing)
- North America
Access these Report: www.alliedmarketresearch.com/checkout/424293
Category: Market Research Publishers and RetailersCompany about: Allied Market Research is a global market research and business consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions”. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market dom ...
For more information: